News

NF-kB Decoy was shown to not only reduce recruitment and proliferation of pro-inflammatory cells but also to induce apoptosis, or cell death, of cells relating to inflammation. NF-kB

In the agreement, Cornerstone has the rights to sell and market the prescription drug in the US, upon FDA approval. Lupin will receive, in aggregate, an amount of

RhuDex is an orally administered small molecule principally indicated for the treatment of rheumatoid arthritis (RA). RhuDex offers a novel approach in the treatment of RA by blocking

A patent appeals board had ruled in favor of Affymetrix, as did the U.S. District Court for the Northern District of California. But the U.S. Court of Appeals

Diovan is now indicated as a potentially life-saving therapy for the more than 750,000 people in the EU who are at risk of a recurrent heart attack or

This is one of several granted and pending patents that protect the company’s ownership of the 5T4 tumor antigen. The granted patent covers immunotherapy products directed against 5T4

The FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) reviewed a print advertisement for Zoloft (sertraline HCl) tablets published in the New York Times magazine last October.

The findings came from three separate studies involving glioblastoma multiforme (GBM), the most common form of brain tumor and the least curable of all human cancers. The first

In fact, when the two are combined, the study showed, the amount of medication required to achieve the same results as use of medication alone can be reduced